The AI system can detect a larger number of high-risk patients across France, Germany, Italy, Spain, and the UK by 2030.

Owkin has partnered with AstraZeneca to develop an AI gBRCA pre-screen solution for breast cancer. Takeaway Points Owkin has ...

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and ...

The solution will use Owkin's data network and artificial intelligence to prescreen for gBRCA mutations in breast cancer directly from digital pathology slides.

Owkin Inc. partnered with Astrazeneca plc to develop an artificial intelligence (AI)-powered tool to pre-screen for germline BRCA mutations (gBRCAm) in breast cancer directly from digitized pathology ...

Inn from the Cold will be announcing a major expansion of services aimed at providing enhanced support to vulnerable Calgary families, to now include expectant mothers. Full details will be revealed ...

Alfa Laval will release third quarter earnings on 24 October at 07:30 am CET. The conference call will start at 09:00 am CET. The conference call is hosted by Alfa Laval's President and CEO Tom Erixon ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Adam, whose name has been changed to protect his identity, has been drinking cups of tea or orange juice secretly laced with drugs since 2021 to enable doctors to administer the AstraZeneca ...

AstraZeneca has agreed a deal worth up to $247 million with US generative artificial intelligence (GenAI) company Absci that will focus on the discovery of a new antibody-based drug for cancer.

AstraZeneca may have exited the COVID-19 vaccine market, but it is still hoping to protect vulnerable patients with its antibody sipavibart for pre-exposure prophylaxis (PrEP). The drugmaker said ...